Ubiquinol
Science / Ingredient Library
Ubiquinol-10, the reduced form of coenzyme Q10 (CoQ10).
100 mg ubiquinol per capsule in Ubiquinol 100 mg.
What ubiquinol is
Ubiquinol is the reduced form of coenzyme Q10. Ubiquinone is the oxidized form. The two forms can convert into one another in the body. CoQ10 takes part in oxidative phosphorylation in mitochondria, the process by which cells use energy from nutrients. The body can make its own CoQ10. Research describes a decline in CoQ10 synthesis with age, which by itself does not establish a deficiency in an individual. [3] [4]
Studies of oral CoQ10 compare preparations that can differ in both chemical form and formulation. The carrier and how the ingredient is formulated can affect how much appears in the blood. A comparison of two capsules therefore measures those specific preparations, and a blood concentration cannot establish a clinical outcome. [4] [7]
What the cocrystal label means
A cocrystal is a single crystalline phase in which two molecular components share a crystal lattice. The Canadian licence lists ubiquinol as the medicinal ingredient. The product packaging identifies the cocrystal form. In this form, ubiquinol and nicotinamide are components of the crystal. The published materials and pharmacokinetic studies below address different questions about the forms they examined. [1] [2] [6]
The published studies do not independently establish the raw-material lot in this product or the clinical effects of the marketed capsule. The studies discussed here examine ingredients or other formulations. They do not establish results for this DR.MORGAN finished product.
Ingredient identity
- Medicinal ingredient
- Ubiquinol
- Amount in Ubiquinol 100 mg
- 100 mg per capsule
- Format and form
- Hard capsule format. Ubiquinol–nicotinamide cocrystal, as identified on the packaging.
- Cocrystal component
- Nicotinamide. The licence lists ubiquinol as the medicinal ingredient.
Licensed product information
Ubiquinol 100 mg · NPN 80139357 · 30 capsules · $39.00 CAD
Recommended use or purpose
(Provides) An antioxidant. Helps to maintain and/or support cardiovascular health.
Medicinal ingredients
Ubiquinol · 100 mg per capsule
Recommended dose
Adults 18 years and older: one capsule once daily.
Recommended duration of use
No specific duration is stated in this product licence.
Cautions and warnings
Consult a health care practitioner/health care provider/health care professional/doctor/physician prior to use if you are pregnant or breastfeeding. Consult a health care practitioner/health care provider/health care professional/doctor/physician prior to use if you are taking blood pressure medication.
Dosage form
Hard capsule format
Selected research on ubiquinol
Ubiquinol and exercise outcomes in trained adults
- Study type
- Randomized, double-blind, placebo-controlled crossover trial.
- Product relevance
- Ingredient evidence from a reduced CoQ10 preparation.
- Sample or population
- 15 exercise-trained adults aged 30–65.
- Studied dose
- 300 mg/day of ubiquinol or placebo.
- Duration
- Four weeks per period with a three-week washout.
- Finding
- Blood total and reduced CoQ10 increased. Exercise performance and oxidative-stress outcomes did not improve overall.
- Limitations
- The small crossover study cannot establish a general exercise benefit. Changes in blood levels do not establish performance effects.
- Study quality
- Placebo-controlled crossover with biochemical and exercise outcomes. Editorial review was limited to the abstract. No formal risk-of-bias rating was assigned.
- Funding and disclosures
- Funding and conflicts were not verified from the abstract.
Ubiquinol and cognitive measures in older adults
- Study type
- Randomized, placebo-controlled human trial.
- Product relevance
- Ingredient evidence for reduced CoQ10.
- Sample or population
- 111 adults aged 60 or older, with 61 assigned to ubiquinol and 50 to placebo.
- Studied dose
- The abstract reports 200 mg of ubiquinol and does not specify dosing frequency.
- Duration
- 90 days.
- Finding
- Plasma CoQ10 was higher with ubiquinol. Adjusted between-group analyses showed no differences in cognition, cardiovascular measures, mood or the reported inflammation and oxidative-stress markers.
- Limitations
- The within-group correlations do not overturn the null between-group findings.
- Study quality
- Randomized comparison with adjusted analyses and exploratory regressions. Editorial review was limited to the abstract. No formal risk-of-bias rating was assigned.
- Funding and disclosures
- Funding and conflicts were not verified from the abstract.
Ubiquinol and exercise capacity in active men
- Study type
- Randomized, double-blind, placebo-controlled human trial.
- Product relevance
- Ingredient evidence for ubiquinol, the reduced form of CoQ10. The trial did not test the DR.MORGAN cocrystal capsule.
- Sample or population
- 54 healthy, recreationally active men.
- Studied dose
- 300 mg/day of ubiquinol or placebo.
- Duration
- 6 weeks.
- Finding
- Plasma CoQ10 increased and a muscle respiration measure suggested more efficient coupling. The groups did not differ in time to exhaustion, the reported oxygen-uptake measures or mitochondrial leak protein levels.
- Limitations
- The trial was limited to active men. Muscle respiration and blood levels do not establish an exercise or clinical benefit.
- Study quality
- Controlled parallel-group study with muscle assays and severe-intensity cycling. Editorial review was limited to the abstract. No formal risk-of-bias rating was assigned.
- Funding and disclosures
- Funding and conflicts were not verified from the abstract. The separate PubMed disclosure reports university and industry co-funding and blinded plasma analysis by the industry co-funder.
Cocrystal ubiquinol: a small pharmacokinetic comparison
- Study type
- Randomized, double-blind, two-period crossover pharmacokinetic pilot in 12 healthy adults.
- Product relevance
- Relevant ingredient evidence; different formulations.
- Finding
- Systemic exposure was higher for the tested cocrystal ubiquinol softgel than for the tested ubiquinone softgel.
- Limitations
- The comparator was ubiquinone. This small, single-dose trial did not test the marketed 100 mg hard capsule or measure clinical outcomes.
- Funding / conflicts
- The company that provided both test products funded the study. One author was affiliated with that company.
How formulation affects CoQ10 blood exposure
- Study type
- Double-blind human crossover pharmacokinetic comparison.
- Product relevance
- Comparative context. The study included both reduced ubiquinol and oxidized ubiquinone preparations and did not test the DR.MORGAN cocrystal.
- Sample or population
- 14 healthy young adults.
- Studied dose
- A single 100 mg dose for each of seven formulations.
- Duration
- Blood measurements over 48 hours. At least four weeks separated doses.
- Finding
- Blood exposure varied substantially. One ubiquinol and one ubiquinone softgel were among the best-absorbed preparations, and the formulation matrix affected exposure.
- Limitations
- Form and formulation were both relevant. A single-dose blood measurement does not establish clinical benefit or general superiority of one form.
- Study quality
- Within-participant comparison using serial plasma measurements. Editorial review was limited to the abstract. No formal risk-of-bias rating was assigned.
- Funding and disclosures
- Funding and conflicts were not verified from the abstract.
Studying a ubiquinol–nicotinamide crystal structure
- Study type
- Solid-state characterization, laboratory tests and rat pharmacokinetics.
- Product relevance
- Indirect relevance; material and animal research.
- Finding
- The authors characterized a ubiquinol–nicotinamide cocrystal and found differences in stability and dissolution under the tested conditions.
- Limitations
- The study did not establish human absorption, clinical benefit, shelf life for the marketed capsule or identity with a commercial lot.
- Funding / conflicts
- The Natural Science Foundation of Shanghai funded the study. The authors declared no conflicts of interest.
Related product
Safety and precautions
Use the licensed product information for this capsule’s directions and cautions. In the Hosoe study, healthy volunteers received single doses of 150 or 300 mg, or 90 to 300 mg daily for four weeks. The manufacturer’s study of its own formulation reported no clinically relevant changes in the standard safety measures it assessed. Those findings apply to the formulation, participants and study period. Formulation can affect absorption, so use the product’s label for directions. If you take prescription medication, are pregnant or are breastfeeding, consult a health care professional before use. [1] [5] [7]
References
- Health Canada. Product licence record, NPN 80139357 (Ubiquinol 100 mg). Licensed Natural Health Products Database.
- Mei X, et al. A Randomized, Double-Blind, Two-Treatment, Two-Period, Crossover Study Investigating the Systemic Bioavailability of a Novel Cocrystal Ubiquinol Formulation Compared with a Ubiquinone Formulation in Healthy Adults. Clin Pharmacol Drug Dev. 2026. DOI: 10.1002/cpdd.70042. PMID 41789786.
- Langsjoen PH, Langsjoen AM. Comparison study of plasma coenzyme Q10 levels in healthy subjects supplemented with ubiquinol versus ubiquinone. Clin Pharmacol Drug Dev. 2014;3(1):13–17. DOI: 10.1002/cpdd.73. PMID 27128225.
- Pravst I, Rodríguez Aguilera JC, Cortes Rodriguez AB, et al. Comparative Bioavailability of Different Coenzyme Q10 Formulations in Healthy Elderly Individuals. Nutrients. 2020;12(3):784. DOI: 10.3390/nu12030784. PMID 32188111.
- Hosoe K, Kitano M, Kishida H, et al. Study on safety and bioavailability of ubiquinol (Kaneka QH) after single and 4-week multiple oral administration to healthy volunteers. Regul Toxicol Pharmacol. 2007;47(1):19–28. DOI: 10.1016/j.yrtph.2006.07.001. PMID 16919858.
- Zhang Q, et al. The Cocrystal of Ubiquinol: Improved Stability and Bioavailability. Pharmaceutics. 2023;15(10):2499. DOI: 10.3390/pharmaceutics15102499. PMID 37896258.
- López-Lluch G, et al. Bioavailability of coenzyme Q10 supplements depends on carrier lipids and solubilization. Nutrition. 2019;57:133–140. DOI: 10.1016/j.nut.2018.05.020. PMID 30153575.
- Bloomer et al. · 2012 · Oxid Med Cell Longev · PMID 22966414
- Nankivell et al. · 2026 · Antioxidants (Basel) · PMID 42510537
- Acton et al. · 2026 · Eur J Appl Physiol · PMID 42249931